Flare Therapeutics raises $85M, names Anna Protopapas CEO to chase prostate cancer
What's the deal? Cambridge-based Flare Therapeutics has closed an $85 million Series C financing led by existing backers Third Rock Ventures and Nextech InvestDealroom has a profile for this one. Try Dealroom →.
The clinical-stage biotech also named industry veteran Anna Protopapas as chief executive officer to steer its next phase of growth.
The round drew a deep bench of investors, including Pfizer VenturesDealroom has a profile for this one. Try Dealroom →, Boxer CapitalDealroom has a profile for this one. Try Dealroom →, GordonMD Global InvestmentsDealroom has a profile for this one. Try Dealroom →, InvusDealroom has a profile for this one. Try Dealroom →, Casdin Capital, Eli Lilly and CompanyDealroom has a profile for this one. Try Dealroom →, NovartisDealroom has a profile for this one. Try Dealroom →, Agent CapitalDealroom has a profile for this one. Try Dealroom →, and Eventide Asset ManagementDealroom has a profile for this one. Try Dealroom →.
Why now? Flare has just completed a strategic review and will concentrate resources on FX-111, a degrader targeting ARON, the hormone-bound androgen receptor in prostate cancer.
The company secured Investigational New Drug clearance from the US Food and Drug Administration and expects to start clinical development in the third quarter of 2026.
FX-111 aims to overcome resistance mechanisms that limit conventional prostate cancer therapies, with potential use across all stages of disease.
What could go wrong? The bet is concentrated: Flare is funnelling capital into one priority program that has yet to prove itself in patients.
A second urothelial cancer drug, FX-909, is now slated for an external partnership rather than in-house advancement, signalling a narrower focus.
Clinical-stage biotechs face long, costly trials, and early-stage oncology assets often fail to clear proof of concept.
The signal: The insider-led round, backed by strategic arms of PfizerDealroom has a profile for this one. Try Dealroom →, Eli LillyDealroom has a profile for this one. Try Dealroom →, and NovartisDealroom has a profile for this one. Try Dealroom →, signals that established pharma still sees value in late-stage precision oncology bets even amid a tight biotech funding market. By installing veteran executive Anna Protopapas and narrowing its pipeline to FX-111, Flare is positioning its transcription factor platform as a focused, clinic-ready prostate cancer play rather than a sprawling discovery engine.
Read more: Business Insider
Image credit: joebeone
